EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy

Bart Geboers iD, Dennie Meijer iD, William Counter, Alexandar Blazevski iD, James Thompson iD, Paul Doan iD, William Gondoputro, Athos Katelaris, Anne-Maree Haynes, Warick Delprado, Gordon O'Neill, Carlo Yuen und 10 weitere

BJU International · 2024-04 · 133 (S4) · 14-22

DOI: 10.1111/bju.16207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, online erschienen am 08.11.2023. Verfasst von Bart Geboers und 21 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the additional value of prostate‐specific membrane antigen positron emission tomography (PSMA‐PET) to conventional diagnostic tools to select patients for hemi‐ablative focal therapy (FT). Patients and Methods We performed a retrospective analysis on a multicentre cohort (private and institutional) of 138 patients who underwent multiparametric magnetic resonance imaging (mpMRI), PSMA‐PET, and systematic biopsies prior to radical prostatectomy between January 2011 and July 2021. Patients were eligible when they met the consensus criteria for FT: PSA 0.5 mm or seminal vesicle involvement at final histopathology. The diagnostic accuracy of mpMRI, systematic biopsies and PSMA‐PET for csPCa (separate and combined) was calculated within a four‐quadrant prostate model by receiver‐operating characteristic and 2 × 2 contingency analysis. Additionally, we assessed whether the diagnostic tools correctly identified patients suitable for hemi‐ablative FT.

Results

In total 552 prostate quadrants were analysed and 272 (49%) contained csPCa on final histopathology. The area under the curve, sensitivity, specificity, positive predictive value and negative predictive value for csPCa were 0.79, 75%, 83%, 81% and 77%, respectively, for combined mpMRI and systematic biopsies, and improved after addition of PSMA‐PET to 0.84, 87%, 80%, 81% and 86%, respectively ( P < 0.001). On final histopathology 46/138 patients (33%) were not suitable for hemi‐ablative FT. Addition of PSMA‐PET correctly identified 26/46 (57%) non‐suitable patients and resulted in 4/138 (3%) false‐positive exclusions.

Conclusions

Addition of PSMA‐PET to the conventional work‐up by mpMRI and systematic biopsies could improve selection for hemi‐ablative FT and guide exclusion of patients for whom whole‐gland treatments might be a more suitable treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiparametric Magnetic Resonance ImagingProstatic NeoplasmsMaleHumansProstateRetrospective StudiesPositron Emission Tomography Computed TomographyGallium RadioisotopesPositron-Emission TomographyBiopsyMagnetic Resonance Imaging

Stichwörter der Autor:innen

PSMA‐PETbiopsyfocal therapympMRIprostate cancer

Substanzen

Gallium Radioisotopes

Autor:innen und Institutionen

  • Garvan Institute of Medical Research & The Kinghorn Cancer Centre, Sydney, NSW, Australia.
  • St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
  • Department of Urology, Amsterdam UMC (location VUmc), Amsterdam, The Netherlands.
  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, NSW, Australia.
  • Department of Urology, St. George Hospital, Sydney, NSW, Australia.

ORCID-Profile: Bart Geboers, Dennie Meijer, Alexandar Blazevski, James Thompson, Paul Doan, Matthijs J Scheltema, Phillip D Stricker

Zitieren

APA

Geboers, B., Meijer, D., Counter, W., Blazevski, A., Thompson, J., Doan, P., Gondoputro, W., Katelaris, A., Haynes, A. M., Delprado, W., O'Neill, G., Yuen, C., Vis, A. N., van Leeuwen, P. J., Ho, B., Liu, V., Lee, J., Donswijk, M. L., Oprea-Lager, D., …, & Stricker, P. D. (2024). Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU International, 133(S4), 14-22. https://doi.org/10.1111/bju.16207

Vancouver

Geboers B, Meijer D, Counter W, Blazevski A, Thompson J, Doan P, et al. Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU International. 2024;133(S4):14-22. doi:10.1111/bju.16207

BibTeX
@article{Geboers2024,
  author = {Geboers, Bart and Meijer, Dennie and Counter, William and Blazevski, Alexandar and Thompson, James and Doan, Paul and Gondoputro, William and Katelaris, Athos and Haynes, Anne-Maree and Delprado, Warick and O'Neill, Gordon and Yuen, Carlo and Vis, Andre N and van Leeuwen, Pim J and Ho, Bao and Liu, Victor and Lee, Jonathan and Donswijk, Maarten L and Oprea-Lager, Daniela and Scheltema, Matthijs J and Emmett, Louise and Stricker, Phillip D},
  title = {Prostate‐specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy},
  journal = {BJU International},
  year = {2024},
  volume = {133},
  number = {S4},
  pages = {14--22},
  doi = {10.1111/bju.16207}
}
Kostenlos starten →